Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? [electronic resource]
Producer: 20190318Description: 383-388 p. digitalISSN:- 1573-7373
- Acetanilides
- Adult
- Aged
- Antineoplastic Agents, Immunological -- adverse effects
- Bevacizumab -- adverse effects
- Biomarkers, Tumor -- genetics
- Brain Neoplasms -- drug therapy
- DNA Methylation
- DNA Modification Methylases -- genetics
- DNA Repair Enzymes -- genetics
- Female
- Follow-Up Studies
- Glioblastoma -- drug therapy
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Pyrroles
- Quinolines
- Retreatment
- Survival Analysis
- Treatment Outcome
- Tumor Suppressor Proteins -- genetics
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.